An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study

Aim. To evaluate effects of ursodeoxycholic acid (UDCA) on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methods. The study included 139 patients with NAFLD who received 15 mg/kg of UDCA (Ursosan®) per da...

Full description

Bibliographic Details
Main Authors:	M. V. Mayevskaya, M. Yu. Nadinskaia, V. D. Lunkov, I. Yu. Pirogova, E. V. Chesnokov, Kh. B. Kodzoeva, V. T. Ivashkin
Format:	Article
Language:	Russian
Published:	Gastro LLC 2020-01-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	non-alcoholic fatty liver disease steatosis cardiovascular risk ursodeoxycholic acid lipid metabolism atherosclerosis
Online Access:	https://www.gastro-j.ru/jour/article/view/449

Similar Items

Use of ursodeoxycholic acid in patients with hypertransaminasemia
by: Claudio Puoti, et al.
Published: (2014-09-01)

Erratum: Mayevskaya M.V. et al., “An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study”
by: article Editorial
Published: (2020-12-01)

Treatment of nonalcoholic fatty liver disease
by: Paul Angulo, MD
Published: (2002-01-01)

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
by: Sahar H. Elhini, et al.
Published: (2022-12-01)

Experience of Using Ursodeoxycholic Acid in Children with Organic Diseases of the Liver
by: Ye.N. Babadzhanian
Published: (2015-03-01)

Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation
by: Xiu-Ping Bai, et al.
Published: (2023-02-01)

Preventive effect of ursodeoxycholic acid on parenteral nutrition-associated liver disease in infants
by: Simić Dušica, et al.
Published: (2014-01-01)

Ursodeoxycholic acid: paradigmatic transformation of the prevention of drug-induced liver lesions in clinical practice
by: Maksim Potjagenko, et al.
Published: (2017-03-01)

May Ursodeoxycholic Acid Significantly Improve Liver Function Tests among Patients with Hepatitis C?
by: Alpaslan Tanoglu, et al.
Published: (2015-12-01)

Use of Ursodeoxycholic Acid on Post-menopausal Obesity, Hepatic steatosis and Plasma Profile as an Alternative Treatment for Hormone Replacement Therapy
by: Angelo Christiano Franzoni, et al.
Published: (2015-12-01)

Liver steatosis in brain death donors
by: D. V. Voronov, et al.
Published: (2021-04-01)

Pleiotropic effects of ursodeoxycholic acid
by: Yu.М. Stepanov, et al.
Published: (2021-06-01)

Association between hypertension and the prevalence of liver steatosis and fibrosis
by: Huanjie Fu, et al.
Published: (2023-04-01)

Influence of ursodeoxycholic acid on insulin resistance in patients with metabolic syndrome
by: V.I. Pankiv
Published: (2018-04-01)

Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy
by: M V Maevskaya, et al.
Published: (2019-02-01)

Morphogenesis of pericellular liver fibrosis in patients with chronic viral hepatitis C associated with hepatic steatosis
by: V. A. Tumanskiy, et al.
Published: (2012-08-01)

Development of a Predictive Model to Induce Atherogenesis and Hepato-Renal Impairment in Female Rats
by: Lucas Pires Guarnier, et al.
Published: (2019-10-01)

Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability
by: Yazmín Karel Melchor-Mendoza, et al.
Published: (2017-05-01)

Experience of using ursodeoxycholic acid in the therapy of biliary sludge in children
by: O.Yu. Belousova, et al.
Published: (2018-04-01)

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid
by: V.N. Santos, et al.
Published: (2003-06-01)

Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
by: Adrian M. Di Bisceglie, et al.
Published: (2020-11-01)

Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Sebastian Zenovia, et al.
Published: (2021-04-01)

Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: The RACURS study
by: S Iu Martsevich, et al.
Published: (2014-12-01)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
by: Hideyuki Tamai, et al.
Published: (2023-02-01)

Alcoholic liver disease: State-of-the-art
by: I V Maev, et al.
Published: (2014-04-01)

Is endocan a novel potential biomarker of liver steatosis and fibrosis?
by: Klisić Aleksandra, et al.
Published: (2020-01-01)

Results of the non-interventional observational program: Influence of Novel COroNavirus on the condition of patients with liver and gastrointestinal Tract diseases and the effect of Ursodeoxycholic acid drugs and Rebamipide on the course of COVID-19 infection (CONTUR)
by: I. N. Tikhonov, et al.
Published: (2022-01-01)

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review
by: Mercedes Robles-Díaz, et al.
Published: (2021-10-01)

Reductive effect of ursodeoxycholic acid on bilirubin levels in neonates on phototherapy
by: Ughasoro MD, et al.
Published: (2019-07-01)

Optimizing the Treatment of Atopic Dermatitis in Infants Using Ursodeoxycholic Acid
by: O.H. Shadrin, et al.
Published: (2016-08-01)

STUDY OF URSODEOXYCHOLIC ACID INFLUENCE ON EFFICACY AND SAFETY OF STATIN THERAPY IN PATIENTS WITH DISEASES OF THE LIVER, GALL BLADDER AND/OR BILIARY TRACT (THE RAKURS STUDY)
by: S. Yu. Martsevich, et al.
Published: (2015-09-01)

Diagnostic accuracy of computer morphometry for steatosis and fibrosis assessment in patients with chronic liver disease of various etiologies
by: Yu.M. Stepanov, et al.
Published: (2023-06-01)

Ursodeoxycholic Acid Can Improve Liver Transaminase Quantities in Children with Anticonvulsant Drugs Hepatotoxicity: a Pilot Study
by: Masoumeh Asgarshirazi, et al.
Published: (2015-06-01)

Liver ultrasound scanning in the detection of hepatic steatosis and fibrosis in NASH patients
by: Mona Hegazy, et al.
Published: (2012-01-01)

Protective effects of ursodeoxycholic acid on ceftriaxone-induced hepatic injury in rats
by: Khaled A. Alhumaidha, et al.
Published: (2014-06-01)

Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia: a case report
by: Mohsen Khosravi
Published: (2020-09-01)

Ursodeoxycholic acid: A therapeutic niche in an internist’s practice
by: O M Drapkina, et al.
Published: (2015-04-01)

Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal
by: Dorotea Bozic, et al.
Published: (2022-09-01)

LIVER DISEASE IN CHILDREN WITH CYSTIC FIBROSIS
by: Laura Mihaela Trandafir, et al.
Published: (2014-03-01)

Non-alcoholic fatty liver disease associated with obesity: features ursodeoxycholic acid
by: D. I. Trukhan, et al.
Published: (2019-04-01)